PPT-IPF Diagnostic Methods and Differential Diagnosis

Content Importance of early diagnosis Initial clues to suspect IPF Guidelines for Diagnosis Diagnostic algorithm for IPF Exclusion of other known causes Other tests and tools . – . The need for early recognition and referral. PRC-2128. It can be difficult to separate idiopathic pulmonary fibrosis (IPF) from other conditions. IPF is a rare but fatal lung disease, with a lower survival rate than many common malignancies. (ILD). Mike McFarlane (CT1). 12/5/12. SLIME. What we’ll cover. Definition. Different types of ILD. Pathophysiology. Presentation. Investigations. Management. Prognosis. Clinical Scenario. Summary. What we won’t.... Comorbidities and Complications. FACULTY. Title. Affiliation. Learning Objectives. Identify approaches to IPF management that are covered in current . guidelines. , taking into account the strength of relevant . Overview of IPF. Overview of IPF (cont). The Role of HRCT in Assessing IPF. HRCT Techniques. Early HRCT Findings in IPF. Hypersensitivity Pneumonitis. HRCT Features and Distribution in Lungs. Definite UIP (All 4 Features). PULMONARY FIBROSIS. 1. By: . Dr.Bidhi. . Chand. Junior Resident Pulmonary Medicine. INTERSTITIAL PULMONARY FIBROSIS. ATS Definition. . Interstitial Pulmonary Fibrosis is defined as a specific form of chronic . FREQUENCY 10k 69 72 75 78 81 84 87 90 GAIN TA01b 100k 1M 10M 100M 1G 60 63 66 Pseudo-Differential Differential)/95dB (Pseudo-Differential)Programmable Compression VoltagesOnboard Reference Reference PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Managing comorbidity. Disclosures. . Scientific Advisory Board and speaker’s fees. Biogen. Idec, . Boehringer. . Ingelheim. ,. Gilead, . Diagnosing Idiopathic Pulmonary Fibrosis. FACULTY. Title. Affiliation. Learning Objectives. Explain the considerations associated with . clinical evaluation, imaging, and . biopsy. , in terms of differentially diagnosing . PULMONARY FIBROSIS MANAGEMENT STRATEGIES I. NOVEMBER 13, 2015. Pharmacologic therapy. Disclosures. Research Grants. Roche (. InterMune. ). Scientific Advisory Board . Roche (. InterMune. ). Boehringer. Discussing Prognosis &. Goals of Care. Sonye K. . Danoff. , MD, . PhD. PULMONARY FIBROSIS. : WHAT AND . WHY. November 13, 2015. No conflict of interest relevant to this presentation. Objective of this talk. Group. : Mohamed . Hairi. Bin Abdul . Shukur. (01DAD10F2060). . Khairil. . Azreen. Bin . Kholid. (01DAD10F2046). Amir Yusuf Bin . Hazimi. (01DAD10F2058). Muhammad . Amin. The . Next Steps in Individualizing Treatment. Learning Objectives. As a result of attending this activity, participants should be able to. :. Select . appropriate therapies that reflect current evidence and/ or widely accepted guidelines that are individualized to patients . Maureen A. Mealy, RN, BSN, Daniel Becker MD, Scott D. Newsome, DO,. John . N. Ratchford, MD, Michael Levy, MD, PhD, Carlos A. Pardo, MD. The Johns Hopkins Transverse Myelitis Center performed a retrospective analysis . When using our slides, please retain the source attribution:. These slides may not be published, posted online, or used in commercial presentations without permission. . Please contact . pce@practicingclinicians.com.